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Improving on the limited success of cancer immunotherapy requires new approaches to inhibit immunosuppressive
pathways initiated by tumor cells to “escape” protective immunity. One unique approach utilizes Salmonella for systemic
delivery of inhibitory RNA, targeting the immunosuppressive molecule Stat3, and a Survivin vaccine to suppress growth
of aggressive murine tumors.
It is now accepted that tumors avoid
destruction by the host immune system
through a multitude of immunosuppres-
sive pathways. Tumors are simultaneously
capable of disabling protective T cells,
activating Tregs and MDSCs, while secret-
ing immunosuppressive molecules to fur-
ther incapacitate anti-tumor immunity.
1
One of the very few approaches targeting
suppressive mediators that has shown clini-
cal efficacy is the FDA approved huma-
nized antibody known as Ipilimumab or
Yervoy
TM, which blocks CTLA-4 function
and profoundly improves survival of
some melanoma patients.
2 However, there
was disappointment when Ipilimumab was
combined with a melanoma-specific pep-
tide vaccine and showed no improvement
in survival. In addition, possible side effects
by Ipilimumab can be life threatening
(FDA box warning) which may limit its
applicability to only patients with advanced
disease. Nevertheless, the concept is
attractive if the design of the combined
immunotherapies could be improved.
In our study published in Cancer
Research,
3 we utilized the unique properties
of Salmonellaasatumor-homingvectorand
as a vaccine. This gave us the flexibility
to target immunosuppressive molecules in
the tumor using shRNA plasmid techno-
logy (shStat3-ST) and to utilize a strong
Salmonella promoter to express tumor
antigen for CTL induction (Max-ST)
(Fig.1). We targeted the multi-functional
molecule Stat3, which has been repeatedly
implicated in tumor survival, proliferation,
angiogenesis and metastasis while promot-
ing expression of immunosuppressive fac-
tors, Treg expansion and inhibition of TH1
immunostimulatory molecules.
4 Our logic
in trying to inactivate Stat3 function was
supported by promising results of small-
molecule and siRNA inhibitors used in
tumors with hyperactivated Stat3 pheno-
types.
5 We combined inactivation of Stat3
with vaccination using Salmonella expres-
sing a versatile TAA known as Survivin
(SVN). SVN isa memberof theinhibitor of
apoptosis (IAP) protein family and possesses
ideal TAA properties: undetectable expres-
sion in non-cancerous adult tissues, over-
expression in most human tumors, and
induces cytotoxic T lymphocytes.
6 SVN is
regulatedbymanypathways includingStat3
transactivation through IL-11 signaling.
7
How did they accomplish the feat
together, when both treatments had far less
activityassingleagents? Increasedimmuno-
suppression caused by larger tumors is
possibly what rendered Max-ST less effect-
ive. The ineffectiveness of shStat3-ST alone
could be explained by differences in its
mode of action compared with other
published Stat3 silencing strategies, for
example CpG-Stat3 siRNA.
5 CpG-Stat3
siRNA has been shown to silence Stat3 in
multiple subsets including CD11b
+ mye-
loid cells, CD11c
+ dendritic cells and
CD19
+ B cells in TDLNs, which may only
occur because it is delivered peritumorally.
shStat3-ST was shown to effectively silence
Stat3 in F4/80
+ macrophage subsets and
it did so when delivered systemically.
Furthermore, silencing by shStat3-ST in
F4/80
+ macrophages was not significantly
different from that seen for CpG-Stat3
siRNA. Although peritumoral treatment
with CpG-Stat3 siRNA showed some
control against subcutaneous B16F10
growth, likely through modulation of
Stat3 expression in multiple immune sub-
sets, it is uncertain whether it would show
any efficacy if delivered systemically.
Based on our study, we can theorize
how the combined treatment worked
synergistically to control larger tumors.
Since the cellular target of shStat3-ST is
macrophages, it is possible that the APC of
choice for Max-ST could also be macro-
phages, either TAMs or those found in
Peyer’s patches. Thus, by silencing Stat3 in
SVN-presenting macrophages, interacting
T cells are more likely to become activated
and proliferate, which could explain the
increases in lymphocyte Ki67 levels we
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observed in tumor-bearing mice receiving
the combined therapy, but not in groups
receiving single treatments.
3 Alternatively,
the silencing of Stat3 in more developed
tumors may re-sensitize them to killing
by SVN-specific responses generated out-
side the proximity of shStat3-ST effect.
Techniques that utilize GFP or luciferase
markersto trackSalmonellainvivo could be
used to study in depth whether shStat3-ST,
given intravenously, and Max-ST, given
orally, co-localize and infect the same cell
targets or exert their effects in different cell
subsets that eventually converge in TDLNs
or in the tumor itself.
The treatment strategy of shStat3-ST
followed by Max-ST is uniquely syn-
ergistic to interrupt a very specific immu-
nosuppressive pathway in TAMs, since we
could not duplicate therapeutic outcomes
using Max-ST vaccination with shRNAs
targeting other macrophage-derived sup-
pressive molecules such as iNOS and
arginase. Exploring possible changes to
downstream events occurring in TAMs
following shStat3-ST administration may
give further insight into the intricate
workings of the combined treatment. For
example, the Stat3-dependent molecule
IL-23, produced by TAMs, has been
shown to activate Stat3 in Tregs, leading
to increased production of the immuno-
suppressive molecule IL-10.
The combined strategy has already
shown considerable efficacy in several
tumor models. Because the timeframe for
Stat3 silencing is finite, tumor escape
eventually occurs, possibly aided by other
survival and immunosuppression pathways
that have yet to be defined. Therefore,
silencing multiple immunosuppressive
targets such as TGF , CTLA-4 and
indoleamine 2,3-dioxygenase could result
in better tumor control. The Salmonella
technology could accommodate testing
these new targets in combination with
SVN vaccination. The excitement of this
approach is the unique combination of
RNA silencing and a vaccination strategy
that have not previously failed clinically
and a solid basis from molecular and
organismic studies affirming its success.
Similar to Ipilimumab, our Salmonella
approach is systemic, giving it favorable
translational feasibility over peritumoral
approaches. Future clinical studies may
confirm its mild toxicity in mice, suggest-
ing a possible advantage over Ipilimumab
in regards to patient safety from severe life-
threatening side effects.
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Figure1. shStat3-ST treatment enhances Max-ST vaccination efficacy. Proposed mechanism of action by combined treatment with shStat3-ST and Max-ST.
Left to right: In a B16F10 tumor-bearing mouse, shStat3-ST is first injected intravenously, followed by oral vaccination with Max-ST. Immunosuppression (red)
developing from hyperactivated Stat3 expression (Stat3P
+) in tumor cells and APCs is targeted by shStat3-ST (green line). Max-ST serves to boost anti-tumor
responses through enhanced expression of SVN within tumor cells or APCs (green arrows) resulting in SVN antigen presentation via MHC class I. The
combined treatment works synergistically to allow for tumor killing by SVN-specific CD8
+ T cells (blue line) leading to tumor regression.
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